FDA approves J&J's Doribax

10/16/2007 | Bloomberg

Johnson & Johnson has obtained regulatory approval to market Doribax as an injectable treatment for serious urinary tract and intra-abdominal infections. J&J licensed Doribax from Japanese drugmaker Shionogi & Co., Ltd. in an effort to address ailments of the urinary tract, which account for 40% of all hospital infections, J&J said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA